FLT3 and cancer: Furthermore, there remains a need for reliable biomarkers of NRF2 inhibition across cancer types, with recent data suggesting that HO-1 expression or downstream redox parameters such as ROS levels or glutathione (GSH/GSSG) ratios may serve as useful indicators in FLT3-mutated AML.